ARIAD provides revise on corporate developments, reports Q1 2014 financial results ARIAD Pharmaceuticals, Inc. The Company provided an update on corporate developments also. As we reintroduce Iclusig in to the U piller .S. Market and continue with the European launch this year, our essential priorities are to rebuild self-confidence in Iclusig also to improve the benefit/risk profile of the drug, said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. Early start data in the U.S. Represent approximately 10 weeks of advertising with a revised item label and show solid marketplace support for Iclusig from community and academic physicians and across a broad spectrum of sufferers with Philadelphia-positive leukemias.
Using the ReSTART site, site visitors can learn about what things to expect when first beginning rehabilitation, steps to make the most of participating in the rehabilitation journey, how to greatest manage transitions between services and healthcare settings, and common financial and legal concerns, such as insurance plan and disability qualification questions. The ReSTART site features an easy to understand glossary also, to help familiarize anyone with one of the most common conditions utilized by rehabilitation healthcare personnel. In addition, visitors will find links to helpful resources and support organizations, and also rehabilitation care planning equipment..